$95.11+0.88 (+0.93%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Kiniksa Pharmaceuticals International (KNSA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~104.8%/yr (FY21→FY25), net margin 8.7%, and free cash flow (~$136.4M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+15.2%) and Capex step-up ($1.6M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲60.1%
677.6
FY21→FY25CAGR +104.8%/yr
Net income ($M)—
59.0
one-off year: see footnoteCAGR −31.5%/yr
Free cash flow ($M)▲440.1%
136.4
capex stepped upCAGR —
Diluted EPS—
0.75
FY22→FY25CAGR −33.9%/yr
What the receipts whisper · what a headline number hides
Share count
+15.2%
68.6mn → 79.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$1.6M
▲265% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
9¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 74.2% → 54.7%. Net margin 8.7% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 945,963.0 | 677,564.0 | 423,239.0 | 270,259.0 | 220,180.0 | 38,544.0 | ▲60.1% | +104.8% |
Cost of revenue | 432,576.0 | 307,218.0 | 189,221.0 | 89,931.0 | 46,966.0 | 9,935.0 | ▲62.4% | +135.8% |
Gross profit | 513,387.0 | 370,346.0 | 234,018.0 | 180,328.0 | 173,214.0 | 28,609.0 | ▲58.3% | +89.7% |
Research & development | 135,769.0 | 96,853.0 | 111,623.0 | 76,097.0 | 65,490.0 | 99,297.0 | ▼13.2% | −0.6% |
Selling, general & admin | 247,153.0 | 196,272.0 | 168,011.0 | 129,427.0 | 97,951.0 | 85,948.0 | ▲16.8% | +22.9% |
Total operating expenses | 382,922.0 | 293,125.0 | 279,634.0 | 205,524.0 | 163,441.0 | 185,245.0 | ▲4.8% | +12.2% |
Operating incomefeeds ROC rank | 130,465.0 | 77,221.0 | −45,616.0 | −25,196.0 | 9,773.0 | −156,636.0 | — | +99.2% (22→25) |
Other income, net | 15,687.0 | 11,647.0 | 9,464.0 | 8,544.0 | 1,253.0 | 97.0 | — | — |
Pretax income | 146,152.0 | 88,868.0 | −36,152.0 | −16,652.0 | 11,026.0 | −156,539.0 | — | +100.5% (22→25) |
Income tax | 36,584.0 | 29,863.0 | 7,041.0 | −30,736.0 | −172,337.0 | 1,385.0 | ▲324.1% | +115.5% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 109,568.0 | 59,005.0 | −43,193.0 | 14,084.0 | 183,363.0 | −157,924.0 | — | −31.5% (22→25) |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 1.31 | 0.75 | −0.60 | 0.20 | 2.60 | −2.30 | — | −33.9% (22→25) |
Diluted shares (mn) | 84.92 | 78.98 | 71.42 | 71.92 | 70.42 | 68.58 | ▲10.6% | +3.6% |
| Margins | ||||||||
Gross margin35th pct in Healthcare | 54.3% | 54.7% | 55.3% | 66.7% | 78.7% | 74.2% | ▼0.6pp | −19.6pp |
Operating margin | 13.8% | 11.4% | −10.8% | −9.3% | 4.4% | −406.4% | ▲22.2pp | +417.8pp |
Net margin72nd pct in Healthcare | 11.6% | 8.7% | −10.2% | 5.2% | 83.3% | −409.7% | ▲18.9pp | +418.4pp |
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was −1563% vs a −1% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was 185% vs a −1% norm for this window, likely a one-time item; see the filing.
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Kiniksa Pharmaceuticals International's revenue last fiscal year?
Kiniksa Pharmaceuticals International reported revenue of $677.6M in fiscal 2025, up 60.1% from fiscal 2024.
What was Kiniksa Pharmaceuticals International's net income?
Kiniksa Pharmaceuticals International reported net income of $59.0M in fiscal 2025, a net margin of 8.7%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

